These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32872166)

  • 1. Literature-Wide Association Studies (LWAS) for a Rare Disease: Drug Repurposing for Inflammatory Breast Cancer.
    Ji X; Jin C; Dong X; Dixon MS; Williams KP; Zheng W
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatments of inflammatory breast cancer: an overview].
    Monneur A; Bertucci F; Viens P; Gonçalves A
    Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on systemic treatment for newly diagnosed inflammatory breast cancer.
    Chainitikun S; Saleem S; Lim B; Valero V; Ueno NT
    J Adv Res; 2021 Mar; 29():1-12. PubMed ID: 33842000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
    Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
    Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
    Ravind R; Kumar PV; Prabaharan S
    BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27060073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A semantic similarity based methodology for predicting protein-protein interactions: Evaluation with P53-interacting kinases.
    Cox S; Dong X; Rai R; Christopherson L; Zheng W; Tropsha A; Schmitt C
    J Biomed Inform; 2020 Nov; 111():103579. PubMed ID: 33007449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
    Goh G; Schmid R; Guiver K; Arpornwirat W; Chitapanarux I; Ganju V; Im SA; Kim SB; Dechaphunkul A; Maneechavakajorn J; Spector N; Yau T; Afrit M; Ahmed SB; Johnston SR; Gibson N; Uttenreuther-Fischer M; Herrero J; Swanton C
    PLoS Med; 2016 Dec; 13(12):e1002136. PubMed ID: 27923043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.
    Wu Y; Warner JL; Wang L; Jiang M; Xu J; Chen Q; Nian H; Dai Q; Du X; Yang P; Denny JC; Liu H; Xu H
    JCO Clin Cancer Inform; 2019 May; 3():1-9. PubMed ID: 31141421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report of bilateral inflammatory breast cancer.
    Masannat YA; Peter M; Turton P; Shaaban AM
    Eur J Cancer Care (Engl); 2010 Jul; 19(4):558-60. PubMed ID: 19708943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of genetic variants and gene network for drug repurposing in colorectal cancer.
    Irham LM; Wong HS; Chou WH; Adikusuma W; Mugiyanto E; Huang WC; Chang WC
    Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review.
    Chainitikun S; Mingmalairak S; Parinyanitikul N
    Chin Clin Oncol; 2021 Dec; 10(6):55. PubMed ID: 34670376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory breast cancer: a single centre analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Repurpose Drugs by Computational Analysis of Disease-Gene-Drug Associations.
    Gopal J; Prakash Sinnarasan VS; Venkatesan A
    J Comput Biol; 2021 Oct; 28(10):975-984. PubMed ID: 34242526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors.
    Santiago-Sánchez GS; Noriega-Rivera R; Hernández-O'Farrill E; Valiyeva F; Quiñones-Diaz B; Villodre ES; Debeb BG; Rosado-Albacarys A; Vivas-Mejía PE
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
    Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.